P3 Health Partners Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended September 30, 2023, not 2022 Q3. Comparisons below are to the three and nine months ended September 30, 2022, as applicable. Figures are in U.S. dollars; financial statement amounts are in millions unless noted.
Business context and reporting period
P3 is a physician-led population health management company, primarily serving Medicare Advantage members through at-risk, capitated contracts with health plans. It reported approximately 105,600 at-risk members, 2,700 affiliated primary care physicians, and operations in 18 markets across five states at quarter-end. Nearly 99% of revenue came from capitation.
Key financial results and changes
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $288.4 | $248.3 | $919.5 | $791.3 |
| Net loss | $37.3 | $65.3 | $117.3 | $1,029.2 |
| Net loss attributable to controlling interest | $13.3 | $11.2 | $32.3 | $176.1 |
| Operating cash flow | Not presented for quarter | Not presented for quarter | $(60.2) | $(94.1) |
| Adjusted EBITDA loss | $22.3 | $40.3 | $41.2 | $87.9 |
- Quarterly revenue grew 16%, including a 17% increase in capitated revenue to $285.2 million. Management attributed capitation growth to higher rates associated with member acuity and 5% membership growth; other patient service revenue fell 25% to $3.2 million.
- Q3 gross profit was $9.1 million, compared with a $6.5 million gross loss a year earlier. Medical margin, a non-GAAP measure, was $36.2 million versus $8.9 million. Nine-month gross profit was $52.5 million versus $3.2 million; medical margin was $126.0 million versus $55.5 million.
- Q3 medical expense increased 10% to $279.2 million, slower than revenue growth. Corporate, general and administrative expense declined 13% to $33.1 million. Nine-month operating loss was $103.7 million, compared with $1,024.4 million, principally because 2022 included an $851.5 million goodwill impairment. No goodwill impairment was recorded in 2023.
- Cash and restricted cash totaled $57.4 million at September 30, 2023, including $52.6 million unrestricted cash. Nine-month cash used in operations was $60.2 million. Financing provided $101.2 million, largely from the 2023 private placement and debt proceeds; cash increased $39.0 million from year-end.
- Long-term debt, net, was $108.3 million, up from $94.4 million at December 31, 2022. Borrowings included a $65.0 million term loan at 12%, a $29.1 million unsecured note at 14%, and a $15.0 million repurchase note at 11% PIK interest. Accrued interest was $21.2 million. The company reported covenant compliance at September 30, but warned future compliance is uncertain.
- Current assets were $179.7 million and current liabilities $267.3 million. Health plan receivables rose to $117.2 million from $72.1 million at year-end; claims payable was $155.5 million.
Outlook, risks, contingencies, and unusual items
- Going concern: Management concluded existing cash resources were not sufficient to support planned operations for at least one year from the filing’s issuance date; substantial doubt exists about the company’s ability to continue as a going concern. It expects continuing operating losses and negative operating cash flows and is exploring additional financing. Financing may be unavailable or costly; equity financing could dilute shareholders, while debt could impose restrictive terms. If funding is unavailable, management may need to curtail planned activities. No specific financial guidance was provided.
- Capital raise and dilution: The April 2023 private placement generated approximately $86.6 million net of offering costs and issued 69.2 million Class A shares, plus warrants and pre-funded warrants. The filing reports 81.9 million warrants outstanding in its potentially dilutive securities table.
- Medical and revenue risks: Results depend on managing medical costs and claims estimates, member acuity and risk adjustment, payor contracts, health-plan quality ratings, and Medicare reimbursement rules. Four health plan customers together accounted for 58% of Q3 revenue and 61% of nine-month revenue in 2023. Management noted seasonality in membership, revenue per member, and medical costs.
- Accounting controls: Disclosure controls were not effective at September 30, 2023 due to continuing material weaknesses, including weaknesses in financial reporting oversight, IT controls, segregation of duties, management review, risk-adjustment revenue, claims estimates, and other accounting areas. Remediation was ongoing and its effectiveness was not assured.
- Cybersecurity: The filing describes an April 2023 business-email-compromise wire fraud attempt that did not cause material losses, and reports a $1.0 million cybersecurity incident loss in the nine-month period. The company warns further incidents could disrupt operations, create liability, and harm its reputation.
- Litigation and other items: A Delaware dispute related to the 2021 business combination has surviving claims in discovery, with a five-day trial scheduled to begin July 22, 2024. A health-plan contract renegotiation settlement had $3.5 million remaining in health plan settlements payable at quarter-end. Intangible assets were $687.9 million, a substantial balance subject to amortization and potential impairment.
Important facts for investors to verify
- Whether P3 secures additional capital in time to address the disclosed going-concern uncertainty, and the terms and dilution associated with any financing.
- Trends in operating cash burn, unrestricted cash, receivable collections, claims payable, and accrued interest.
- Whether growth in capitated revenue and membership translates into sustained improvement in gross profit and medical margin after medical costs and reserve adjustments.
- Progress in remediating material weaknesses and whether controls become effective in subsequent filings.
- Debt covenant compliance and the company’s capacity to service high-interest debt, alongside developments in the Hudson litigation and cybersecurity controls.